Secondary analysis of the phase 3 LUSTRE trial (233 patients, inoperable stage I NSCLC): SBRT gave higher global health scores than hypofractionated radiotherapy at 2 weeks (difference 4.00) but slightly lower at 24 months (difference -2.92).
Secondary analysisn = 233 patients
Hou et al. Quality of Life of Stereotactic Versus Hypofractionated Radiation Therapy for Inoperable Stage I Non-Small Cell Lung Cancer: Results From the LUSTRE Trial